Dr. Richard Graham explains how FDA’s new program allows for the usage of real-time data during clinical trials. In April, FDA announced plans for a pilot program to allow for real-time data review ...
Biotech’s ~10-year path from private risk to approved therapy is mismatched with trading-driven capital markets, where minor ...
David Crean, chief business officer at MedicNova, discusses changes at FDA causing variability and unpredictability in ...
In the third part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, traces the origins of ...
In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic ...
According to him, the industry must address its relationship with the capital markets, address misinformation issues, and push back against the politicization of medical research and development.
Toragen is uniquely positioned to navigate this dynamic. Its HPV E5 inhibitor addresses indications that span both sexes: HPV-positive head and neck cancer affects predominantly men, cervical cancer ...
Hypereosinophilic syndrome is defined by persistent eosinophilia with eosinophil-mediated organ/tissue damage, driving ...
The takeaway leadership message from our May issue is clear: Future progress will come from those willing to rethink the machinery — not just the medicine. If there’s a common thread running through ...
A full clinical hold suspends dosing and enrollment in the Phase III HERO study and open-label extension, superseding the earlier voluntary pause and freezing near-term registrational timelines.
The current prior authorization (PA) process is an administrative failure. Beyond the excessive time and paperwork required, ...
In the first part of her interview with Pharmaceutical Executive, Sandra Coufal, MD, CEO of Toragen, explains why the HPV E5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results